Evidence-Based Complementary and Alternative Medicine

Review Article

Efficacy and Safety of Re Du Ning Injection for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Table 1

Studies characteristics.


Author	Sample size (EG/CG)	Mean age (EG/CG)	Experimental intervention	Cointerventions	Course of treatment (days)	Outcomes

Zeng et al. [25]	116/110	—	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator; PRM; AD	10	C, D
Chen et al. [21]	77/77	64.7/65.8	RDN 20 ml ivgtt qd	Antibiotics; PRM; AD	7	A, B, C, E, F, G, H, I
Chen et al. [23]	30/30	—	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator; AD; oxygen therapy	10	A
Dong et al. [22]	30/30	62.3/61.3	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator; PRM	7	A
Tian 2015 [36]	37/37	59.7/60.8	RDN 20 ml ivgtt qd	Antibiotics; PRM; AD	10	A, C
Zhang et al. [24]	45/41	55/57	RDN 20 ml ivgtt qd	Antibiotics; PRM; AD	3	A
Liu et al. [34]	80/80	68.2/66.8	RDN 20 ml ivgtt qd	Antibiotics; PRM; AD	14	A
Yao [33]	50/50	62.1/62.4	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator PRM; AD; oxygen therapy	7	A
Weng et al. [32]	40/40	57/58	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator	5	A
Xu et al. [28]	15/15	—	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator; PRM; AD; oxygen therapy	7	A
Gao et al. [30]	38/39	66/63	RDN 20 ml ivgtt qd	Antibiotics; AD; oxygen therapy	5	A, H
Nie et al. [29]	50/50	72.4/70.2	RDN 20 ml ivgtt qd	Antibiotics; oxygen therapy	3	E, F, G, H, I
Tang [27]	45/45	63/63	RDN 20 ml ivgtt qd	Antibiotics; PRM; oxygen therapy	14	A, B, C, H, I
Pang et al. [26]	55/55	55/54	RDN 20 ml ivgtt qd	Antibiotics; PRM; AD; oxygen therapy	14	A, D, E, F, G
Lu [20]	44/44	65.9/67.1	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator; PRM	7	A
Wan [18]	48/48	58.9/59.5	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator; PRM	7	A
Wei [17]	37/33	—	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator; PRM	10	A, B, C
Zhou 2014 [16]	30/30	72.6/73.1	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator; PRM	7	A, E, F, G, H
Zhang [14]	45/44	66.2/65.7	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator; PRM; AD; oxygen therapy	10	A, H
Ye et al. [13]	40/40	62.8/62.4	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator; PRM	28	A, C
Yang et al. [12]	30/30	64.5/64.2	RDN 20 ml ivgtt qd	Antibiotics; bronchodilator; PRM; AD; oxygen therapy	10	A, I
Zhang et al. [35]	45/42	66.2/65.7	RDN 20 ml ivgtt qd	Antibiotics; PRM; AD	10	A, H
Yue [19]	33/32	73/70	RDN 20 ml ivgtt qd	Antibiotics; AD	14	A, H
Peng et al. [15]	26/26	65.0/62.9	RDN 20 ml ivgtt qd	Antibiotics; PRM; AD	10	A
Tong [37]	39/39	64.2/63.8	RDN 20 ml ivgtt qd	Antibiotics; AD	10	A
Xu et al. [31]	26/26	62.7/61.4	RDN 20 ml ivgtt qd	Antibiotics; PRM	10	A, I

EG: experimental group; CG: control group; PRM: phlegm resolving medicine; AD: antiasthmatic drugs; RDN: Re Du Ning injection; ivgtt: intravenous drip; qd: once a day; A: response rate; B: FEV₁; C: FEV₁/FVC; D: T-lymphocyte E: PH; F: PaO₂; G: PaCO₂; H: C-reactive protein; I: procalcitonin.